{"id":684,"date":"2014-09-16T18:41:03","date_gmt":"2014-09-16T18:41:03","guid":{"rendered":"http:\/\/stg-blogs.bmj.com\/jmg\/?p=684"},"modified":"2014-10-01T15:47:41","modified_gmt":"2014-10-01T15:47:41","slug":"defining-and-managing-incidental-findings-in-genetic-and-genomic-practice","status":"publish","type":"post","link":"https:\/\/stg-blogs.bmj.com\/jmg\/2014\/09\/16\/defining-and-managing-incidental-findings-in-genetic-and-genomic-practice\/","title":{"rendered":"Defining and managing incidental findings in genetic and genomic practice"},"content":{"rendered":"<p>Our review explored questions about the management and disclosure of incidental genomic findings\u2014those discovered through whole-genome approaches, but unrelated to the question that was asked. We have discussed the various terms used for such findings; factors that determine disclosure; differences in clinical, research and commercial settings; and ethical\/practical issues about familial implications and re-contacting testees. Our recommendations include that greater international consensus is developed around disclosure and management; findings are referred to in appropriately different ways according to context; clear consent processes are used, but the absence of consent should not always preclude disclosure; and ways to use the genome output as a resource, accessible over time, are identified, particularly to facilitate disclosure and re-contact when previously unclear findings are clarified. (By Dr Sandi Dheensa, <a href=\"http:\/\/jmg.bmj.com\/content\/early\/2014\/09\/16\/jmedgenet-2014-102435\">http:\/\/jmg.bmj.com\/content\/early\/2014\/09\/16\/jmedgenet-2014-102435<\/a> )<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Our review explored questions about the management and disclosure of incidental genomic findings\u2014those discovered through whole-genome approaches, but unrelated to the question that was asked. We have discussed the various terms used for such findings; factors that determine disclosure; differences in clinical, research and commercial settings; and ethical\/practical issues about familial implications and re-contacting testees. [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/stg-blogs.bmj.com\/jmg\/2014\/09\/16\/defining-and-managing-incidental-findings-in-genetic-and-genomic-practice\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-684","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/stg-blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg-blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stg-blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=684"}],"version-history":[{"count":0,"href":"https:\/\/stg-blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/684\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg-blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}